Literature DB >> 16092117

Diagnostic significance of reduced serum caeruloplasmin concentration in neurological disease.

John M Walshe1.   

Abstract

This study covers patients seen at a Wilson disease clinic between 1960 and 2002. The diagnosis of Wilson disease was confirmed in 316. Of 40 patients with a neurological presentation who were found not to have the disease, caeruloplasmin concentration was found to be reduced in 19. These 19 patients comprised 17 men and 2 women. The various diagnoses included Huntington's disease, multiple sclerosis, subacute sclerosing panencephalitis (SSPE), Hallervorden Spatz syndrome, and acaeruloplasminemia; in 9 no definite diagnosis was made. In view of the marked male preponderance, the lower limit of caeruloplasmin is calculated as for males. In an earlier study this was found to be 33.3 mg/dl (standard deviation, 6.1 mg/dl); therefore, 21.1 mg/dl is taken as the lower limit of normal. Particular attention is paid to 3 patients, 2 of whom had zero concentrations of caeruloplasmin and 1 had a very low level of the protein. Only 1 of these patients conformed to the classical picture of acaeruloplasminemia. The significance of a low caeruloplasmin concentration in patients with a variety of neurological syndromes is not clear but can lead to diagnostic confusion. When the concentration of this protein is very low or absent the diagnosis of acaeruloplasminemia must be considered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16092117     DOI: 10.1002/mds.20628

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  Hepatobiliary quiz-9 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-03

Review 2.  A review and current perspective on Wilson disease.

Authors:  Mallikarjun Patil; Keyur A Sheth; Adarsh C Krishnamurthy; Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2013-07-06

Review 3.  Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action.

Authors:  Ana Muñoz-Jurado; Begoña M Escribano; Javier Caballero-Villarraso; Alberto Galván; Eduardo Agüera; Abel Santamaría; Isaac Túnez
Journal:  Inflammopharmacology       Date:  2022-06-05       Impact factor: 5.093

4.  Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease.

Authors:  Da-Wu Zeng; Yu-Rui Liu; Jie-Min Zhang; Yue-Yong Zhu; Su Lin; Jia You; You-Bing Li; Jing Chen; Qi Zheng; Jia-Ji Jiang; Jing Dong
Journal:  PLoS One       Date:  2013-10-25       Impact factor: 3.240

5.  The optimal threshold of serum ceruloplasmin in the diagnosis of Wilson's disease: A large hospital-based study.

Authors:  Rong Xu; Yong-Fang Jiang; Yong-Hong Zhang; Xu Yang
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

6.  Hypocupremia: a possible association with late cortical cerebellar atrophy.

Authors:  Shivam Om Mittal; Duarte G Machado
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-09-09

7.  Changes in Serum Ceruloplasmin Levels Based on Immunomodulatory Treatments and Melatonin Supplementation in Multiple Sclerosis Patients.

Authors:  Monika Adamczyk-Sowa; Paweł Sowa; Sebastian Mucha; Jacek Zostawa; Bogdan Mazur; Maciej Owczarek; Krystyna Pierzchała
Journal:  Med Sci Monit       Date:  2016-07-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.